- Not Fee assured
- Verified account
- Surgical retinal
Robert MacLaren is Professor of Ophthalmology at the University of Oxford, Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology, Honorary Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital, Honorary Consultant Ophthalmologist at Great Ormond Street Children's Hospital, Faculty Member and Founding Theme Leader of the Moorfields-UCL, Institute of Ophthalmology Biomedical Research Centre. From 2010-2012 he was also Theme Leader for Brain Research at the Oxford Biomedical Research Centre. He is also a Fellow of the Royal College of Ophthalmologists, Fellow of the Royal College of Surgeons of Edinburgh, Fellow of the American College of Surgeons, Fellow of the Academy of Medical Sciences and Bodley Fellow of Merton College Oxford.
Previous notable achievements in ophthalmic surgery include defining the equations for lens power predictions for cataract surgery in extreme myopia (J Cataract Refract Surg 2005) and hyperopia (Am J Ophthalmol 2007); the first in human gene therapy trial for choroideremia (Lancet 2014; New Engl J Med 2016; Nature Med 2018); the first ever use of a robot to operate inside the human eye (Nature Biomed Eng 2018); the first gene therapy treatment to reverse vision loss in retinitis pigmentosa (Nature Med, 2020) and the first gene therapy trial for the dry form of age-related macular degeneration, together with Gyroscope Therapeutics (www.bbc.co.uk/news/health-47226987).
Areas of interest
Cataract surgery; Cataracts; Age related macular degeneration (AMD); Eyes; Diabetic retinopathy; Retinal disease / surgery; Visual disorders; Medical retina; Vitreoretinal surgery; Anterior segment surgery (eyes);
- Raluca Guta
- Practice Manager to Prof MacLaren Nuffield Health The Manor Hospital Beech Road Headington Oxford OX3 7RP
- 01865 307768
Anaesthetists worked with
Current NHS consultant posts held
Consultant Ophthalmologist at the Oxford Eye Hospital and Honorary Consultant at Moorfields Eye Hospital
Clinical and laboratory research is dedicated to finding new treatments for blindness, particularly in patients with incurable retinal diseases. Includes developing gene therapy with adeno-associated viral (AAV) vectors in the lab and in forthcoming clinical trials.
A clinical research program in artificial vision with bio-genetic and electronic devices. Developing new eye surgery techniques for age-related macular degeneration, cataract and macular hole surgery.
Prior to ophthalmology, Robert was commissioned into the Royal Army Medical Corps. He saw active service as a Section Commander with 16 Armoured Field Ambulance and latterly served as the Surgeon Major to the Honourable Artillery Company in London. He remains a keen supporter of the military and provides concessions for former service personnel. In 2004 he was awarded the Volunteer Reserves Service Medal (VR) and in 2011 he was appointed as Civilian Consultant Advisor to the Royal Navy.
2020 Lang Lecture and Medal, Royal Society of Medicine
2020 Senior Investigator Award, National Institute for Health Research
2019 Clinical Service of the Year Award, the Macular Society
2019 Keeler Lecture and Medal, Royal College of Ophthalmologists
2019 Gold Clinical Excellence Award for NHS service delivery
2018 Sir Adrian Cadbury Lecture and Medal, Midland Ophthalmological Society
2018 American Academy of Ophthalmology Achievement award
Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.
Cehajic-Kapetanovic J. et al, (2020), Nature Medicine, 26, 354 - 359
Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia.
Xue K. et al, (2018), Nature Medicine, 24, 1507 - 1512
First-in-human study of the safety and viability of intraocular robotic surgery.
Edwards TL. et al, (2018), Nature Biomedical Engineering, 2, 649 - 656
Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy.
De Silva SR. et al, (2017), Proceedings of the National Academy of Sciences, 114, 11211 - 11216
Visual Acuity after Retinal Gene Therapy for Choroideremia.
Edwards TL. et al, (2016), N Engl J Med, 374, 1996 - 1998
Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization.
Charbel Issa P. et al, (2015), Proc Natl Acad Sci U S A, 112, 8415 - 8420
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.
MacLaren RE. et al, (2014), Lancet, 383, 1129 - 1137
Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation.
Singh MS. et al, (2013), Proc Natl Acad Sci USA, 110, 1101 - 1106
Retinal repair by transplantation of photoreceptor precursors.
MacLaren RE. et al, (2006), Nature, 444, 203 - 207
- MB ChB University of Edinburgh 1990
- DPhil University of Oxford 1996
- FRCS (Edin) Royal College of Surgeons of Edinburgh 1998
- FRCOphth Royal College of Ophthalmologists 2004
- FACS American College of Surgeons 2017
- FMedSci Academy of Medical Sciences 2018
Reference number 3493087
Professional bodies (positions held - last 3 yrs)
- Civilian Consultant Advisor The Royal Navy 2011
- Specialist Advisor The National Institute for Health and Care Excellence (NICE) 2019
Details of entry to specialist register
- Specialist Register (Ophthalmology), 2003
Post treatment communication
In the event of an urgent query following treatment, Bupa members should use the following contact details